What will cancer treatment of the future look like?

It may well include unpatentable approaches like
Gerson’s and Coley’s. It will probably involve readily
available agents used off-the-shelf, off-label.


When cancer strikes, most people lack confidence in their cancer institutions. They are not prepared to navigate unfamiliar treatment options such as surgery, radiation, chemotherapy, targeted agents. They hear the hyped but poorly defined term immunotherapy, but immunotherapies are not approved or available in conventional cancer centers for the kinds of cancer most people get. The Gerson Research Organization is a voice for the reform of mainstream cancer research and treatment, for taxpayer-funded research into well-known “unproven treatments”, and an advocate for wide adoption of safe and effective immunotherapy.

What Is Immunotherapy?

Matzinger suggests that a correct definition of the immune system includes every tissue in the body. This includes our organs, vessels, muscles, nerves, the circulating liquid tissues of blood and lymph, etc. All tissues. In fact, all immune responses are started by the damaged tissue with a molecular call for help. If an injured tissue is metabolically suppressed, it will not easily produce distress signals. Sick tissues need intelligent inputs. If the goal is to use immunotherapy against cancer, it must be an integrative discipline that draws on every specialty to ask what can be done to improve the function of all tissues? What can we do to raise the counts of immune cells (liquid tissue) and activate them? What methods are available to wound a tumor in order to make it visible to the immune system (the immune system sees only wounds and microbes). Intelligent immunotherapy is responsible for improving the function of every tissue in the body.

Play Video

Why Your Body Needs Danger

Dr Polly Matzinger, an NIH Section Chief and Senior Scientist at NIAID's Immunogenetics Laboratory, conceived and explicated the Danger Model to describe how the immune system really functions. Applications of this model have brought about innovations in clinical practice, leading to better strategies for transfusions, transplants, and cancer treatment. The Danger Model predicts a way forward to more successful ways to use the immune system to clear tumors. Dr Matzinger held an invited conference on Danger for NIH scientists, and NIH captured it on video. All 8 of Dr Matzinger's lectures are available, courtesy of the NIH Videocast Library.

Coley's Toxins

The science is settled. More than a century after its debut, Coley Fluid is still the most effective single-agent immunotherapeutic against cancer. So where is it? The historical record reveals intrusion into the biological sciences by a confederacy of dunces in NIH, FDA and Congress. Read the documentation in newspaper and Federal Register reports about the failure of NIH’s immunology lab in the 1960s to ensure effective vaccine manufacture, the kneejerk reaction by Congress to put NIH's immunology lab under FDA, the failure of FDA to understand how to properly evaluate biologicals, and a 34-year impermeable barrier to research on the Coley microbe including a 27-year ban on Streptococcus pyogenes itself. Because of the lingering effects of bureaucratic bungling, Big Pharma and Big Bio believe Coley is untouchable. Consider signing on as an advocate for scientific reparations, to request that NIH and FDA collaborate to fill this research void and conduct basic and translational research on this unbelievably cool observation.

The Way-Back Machine

Nearly a century ago, Gerson, et al, established proof of principle by demonstrating reversal of refractory skin tuberculosis under the influence of nutritional immunotherapy alone. All immune responses originate in tissue, and Gerson's obsession with measures that could improve tissue health resulted in a successful strategy against tuberculosis. The same measures can be employed as part of a methodologically integrated cancer treatment system.

Click To The Future

Danger predicts that repeatedly wounding tumors while tending immune-cell populations can result in a series of lymphocyte-effector responses that can clear tumors. Please read our discussion of the complete remission from recurrent, bulky mantle-cell lymphoma in only 2 months (the MSKCC protocol he refused would have run 9 months with a 25% risk of mortality from the drugs). This was the first patient treated by our colleagues of St Andrews Clinic with our current methodology, which is built around Gerson and Coley, but also includes modern materials and methods.


If you are in need of first line treatment, or are currently undergoing treatment with unfavorable results, click here.


We encourage people in oncology and related disciplines to be aware of the Danger Model and the historical treatments of Coley and Gerson, which bolster its tenets.


If you have the freedom, time and resources in your lab (we’re talking to you, NIH) to begin a disciplined inquiry into the above treatments, we are at your service. NIH needs a coordinating office, in the Office of the Director, called the Office of Neglected Cool Observations.

Real Live Patient

Purpose of the Gerson Research Organization

The purpose of the Gerson Research Organization is to conduct and publish the results of public interest research into the role of nutrition and vaccine-based immunotherapies in the management of cancer and other diseases, to publish educational materials pertinent to the public interest, and to conduct public forums, lectures, and policy reform campaigns focused on the role of nutrition in health and the roles of dietotherapy and vaccines in disease management.

GRO is a nonprofit 501c(3) public benefit corporation for scientific research and service to patients and professionals.

Connect with us